Farnaz Fahimi, Mohammad Reza Tohidkia, Mehdi Fouladi, Reza Aghabeygi, Naser Samadi, Yadollah Omidi* 
|
Mohammad Mostafa Pourseif, Gholamali Moghaddam*, Hossein Daghighkia, Ahmad Nematollahi, Yadollah Omidi*
|
Ananda Mookerjee, Michele Graciotti, Lana E. Kandalaft*
|
Sepideh Parvizpour, Jafar Razmara, Yadollah Omidi*
|
Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif, Yadollah Omidi*
Using
immunoinformatic tools, a multi-epitope peptide vaccine (consisting of CD8+cytotoxic T lymphocytes epitopes, helper epitopes and
adjuvant) was designed to combat the triple-negative breast cancer. The vaccine
showed acceptable immunogenicity and potential to stimulate both cellular and
humoral immune responses.
|
Original Research
COVID-19
Mohammad Mostafa Pourseif , Sepideh Parvizpour, Behzad Jafari, Jaber Dehghani , Behrouz Naghili, Yadollah Omidi*
Immunodominant T-cell epitopes of SARS-CoV-2 spike protein with the highest population coverage were predicted by analyzing peptide binders and consensus rank (CR) score. Multi-method B-cell epitope prediction approach was used to find B-cell immunodominant regions of spike protein. Upon the high immune-potent regions of the antigen(s), self-amplifying mRNA and peptide-based vaccines were designed.
|
Ysrafil Ysrafil* , Zulfiayu Sapiun , Indwiani Astuti , Mohammad Anas Anasiru, Nangsih Sulastri Slamet , Hartati Hartati , Fadli Husain, Sukmawati Ahmad Damiti
The two designed and constructed multiepitope vaccine have good characteristics and may have the potential to activate humoral and cellular immune responses against SARS-CoV-2. Further research is worth considering to confirm the findings of this study.
|
Leila Rostamizadeh , Ommoleila Molavi* , Mohsen Rashid, Fatemeh Ramazani, Behzad Baradaran, Afsaneh Lavasanaifar, Raymond Lai
In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.
|
Azam Safary , Mostafa Akbarzadeh-Khiavi , Jaleh Barar , Yadollah Omidi*
Professor Yadollah Omidi has a Ph.D. degree in Pharmaceutical Sciences (2003, Cardiff University, UK). He is currently working as a full professorat Nova Southeastern University College of Pharmacy, Florida. He has consecutively been listedamong top 1% highly cited scientists worldwide by WoS-ESI.
|
Maryam Rezaei , Mehri Habibi, Parasoo Ehsani, Mohammad Reza Asadi Karam*, Saeid Bouzari*
|
Hamed Zare , Hamid Bakherad* , Arman Nasr Esfahani, Mohamad Norouzi, Hossein Aghamollaei, Seyed Latif Mousavi Gargari, Fatemeh Mahmoodi, Mahdi Aliomrani, Walead Ebrahimizadeh
|
Sari Eka Pratiwi* , Ysrafil Ysrafil , Mardhia Mardhia , Mahyarudin Mahyarudin , Muhammad Inam Ilmiawan, Heru Fajar Trianto, Delima Fajar Liana, Yuri Amia
|